NCT04904250 (CASH-ES) is a NA clinical trial of Emboshield in Stroke, sponsored by Xuanwu Hospital, Beijing.

Who is sponsoring NCT04904250?

NCT04904250 is sponsored by Xuanwu Hospital, Beijing.

What drugs are being tested in NCT04904250?

Interventions in NCT04904250: Emboshield, Spider.

What condition does NCT04904250 study?

NCT04904250 studies Stroke, Carotid Stenosis, Carotid Artery Stent.

Is NCT04904250 still recruiting?

NCT04904250 is currently status unknown. Last updated 30 June 2022.

Last reviewed 2022-06-30 · How we verify

NCT04904250: CASH-ES

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spider Versus Emboshield Distal Protection on Cerebral Microembolization During Vulnerable Plaque in Carotid Artery Stenting

Status unknown NA Last updated 30 June 2022

What this trial tests

NA trial testing Emboshield in Stroke in 172 participants. Status unknown.

Timeline

27 August 2022

Primary endpoint
31 May 2024

1 October 2024

Quick facts

Lead sponsor	Xuanwu Hospital, Beijing
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	single
Primary purpose	treatment
Enrollment	172
Start date	27 August 2022
Primary completion	31 May 2024
Estimated completion	1 October 2024
Sites	1 location across China

Drugs / interventions tested

Emboshield
Spider

Conditions studied

Stroke — all drugs for Stroke →
Carotid Stenosis — all drugs for Carotid Stenosis →
Carotid Artery Stent — all drugs for Carotid Artery Stent →

Sponsor

Xuanwu Hospital, Beijing

Who can join

18 and older, any sex, with Stroke or Carotid Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single center, prospective, outcome-assessor-blinded, randomized controlled trial study (CASH-ES) is designed to compare the efficiency of two different distal embolism protection devices (SpiderFX and Emboshield NAV6) in during CAS procedure of patients with vulnerable plaque.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Two different distal protections on cerebral microembolization of vulnerable plaque during carotid artery stenting (CASH-ES): study protocol for a randomized controlled trial.
Yan L, Shu L, Xinyi S, Zhang N, et al · · 2026 · PMID 42001098 · DOI 10.1186/s13063-026-09687-3

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07356011 — Exoskeleton for Balance · NA · recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04904250 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
Last refreshed: 30 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04904250.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing